Subscribe to our newsletter to receive the latest product updates and special offers

HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoBacktestsElite
Theme 		Help

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Earnings

Review historical estimates and see whether a company has beaten or missed expectations.

MIRA

Mira Pharmaceuticals Inc

Last Close
Jun 14 • 04:00PM ET
0.7380
Dollar change
+0.0279
Percentage change
3.93 		%
Scroll to Statements
Index- P/E- EPS (ttm)-0.81 Insider Own34.05% Shs Outstand14.78M Perf Week-2.89%
Market Cap10.91M Forward P/E- EPS next Y-0.40 Insider Trans-4.36% Shs Float9.75M Perf Month4.78%
Income-12.36M PEG- EPS next Q-0.10 Inst Own4.20% Short Float1.10% Perf Quarter-37.46%
Sales0.00M P/S- EPS this Y3.13% Inst Trans- Short Ratio0.76 Perf Half Y-46.52%
Book/sh0.21 P/B3.46 EPS next Y35.48% ROA-587.64% Short Interest0.11M Perf Year-
Cash/sh0.24 P/C3.09 EPS next 5Y- ROE-1807.80% 52W Range0.63 - 7.98 Perf YTD-29.71%
Dividend Est.- P/FCF- EPS past 5Y- ROI-391.51% 52W High-90.75% Beta-
Dividend TTM- Quick Ratio5.70 Sales past 5Y0.00% Gross Margin- 52W Low16.98% ATR (14)0.08
Dividend Ex-Date- Current Ratio5.70 EPS Y/Y TTM- Oper. Margin0.00% RSI (14)42.82 Volatility6.29% 14.36%
Employees3 Debt/Eq0.00 Sales Y/Y TTM- Profit Margin- Recom- Target Price-
Option/ShortNo / Yes LT Debt/Eq0.00 EPS Q/Q4.18% Payout- Rel Volume0.30 Prev Close0.71
Sales Surprise- EPS Surprise0.00% Sales Q/Q- EarningsMay 29 Avg Volume140.71K Price0.74
SMA20-8.61% SMA50-11.13% SMA200-61.93% Trades Volume42,094 Change3.93%
Jun-10-24 08:30AM
Mira Pharmaceuticals Announces Positive Preclinical Study Results For Its Novel Oral ketamine Analog, Ketamir-2, Paving the Way for IND Submission Later This Year
(PR Newswire)
May-29-24 08:45AM
Mira Pharmaceuticals Announces DEA Rules MIRA-55, a Novel Oral Pharmaceutical Marijuana Analog, Is Not Classified as a Controlled Substance
(PR Newswire)
May-21-24 08:45AM
MIRA Pharmaceuticals in Discussions with Memorial Sloan Kettering to Collaborate on Preclinical Cancer Pain Model Utilizing The Company's Novel Oral Ketamine Analog
(PR Newswire) +20.00%
May-20-24 08:00AM
Mira Pharmaceuticals Advances Preclinical Trials Towards an IND Submission This Year for Ketamir-2, a Differentiated Oral Ketamine Analog
(PR Newswire) +29.77%
May-13-24 09:53PM
MIRA Stock Earnings: Mira Pharmaceuticals Misses EPS for Q1 2024
(InvestorPlace)
08:00AM Loading…
Apr-02-24 08:00AM
Mira Pharmaceuticals Announces Encouraging Preclinical Results Advancing Ketamir-2 Towards Potential Year-End IND Submission
(PR Newswire)
Apr-01-24 02:53PM
MIRA Stock Earnings: Mira Pharmaceuticals Beats EPS for Q4 2023
(InvestorPlace)
Mar-21-24 11:04AM
MIRA Pharmaceuticals Welcomes Dr. Itzchak Angel, former Head of Pharmacology at Synthelabo, as Chief Scientific Advisor
(PR Newswire)
Mar-08-24 08:19AM
Why Is Mira Pharmaceuticals (MIRA) Stock Up 52% Today?
(InvestorPlace) +65.28%
Feb-05-24 08:30AM
MIRA Pharmaceuticals Provides Corporate Update
(PR Newswire) +45.99%
Dec-04-23 08:00AM
MIRA Pharmaceuticals Releases Breakthrough Data from Artificial Intelligence Simulations
(PR Newswire) -5.26%
Nov-29-23 08:00AM
MIRA Pharmaceuticals Announces Ketamir-2's Oral Bioavailability Predicted to be 80%
(PR Newswire)
Nov-21-23 10:42AM
MIRA Pharmaceuticals To Host Shareholder Update Call on Tuesday, December 5, 2023 at 11:30 a.m. Eastern Time
(PR Newswire) -16.13%
10:09AM
MIRA Pharmaceuticals Announces Paradigm-Shift in Cognitive Enhancement with MIRA1a
(PR Newswire)
Nov-20-23 08:00AM
MIRA Pharmaceuticals Announces Exclusive Licensing Agreement for Oral Ketamine Analog, Ketamir-2
(PR Newswire) +40.06%
07:23AM Loading…
Oct-26-23 07:23AM
MIRA: Developing Cannabis with Benefits and Without Side Effects
(Zacks) +5.38%
Sep-18-23 08:30AM
MIRA Pharmaceuticals Shows its Prescription Pill More Palatable and Potent Than Pot
(PR Newswire) +38.80%
Sep-05-23 08:31AM
MIRA Pharmaceuticals and MZ Group Partner to Strengthen Investor Relations and Shareholder Communication Efforts
(PR Newswire)
Aug-31-23 08:31AM
MIRA Pharmaceuticals to Participate in 6th Annual Cannabinoid-Derived Drug Development Summit
(PR Newswire)
Aug-29-23 11:39AM
MIRA Pharmaceuticals to Host Virtual Roadshow Webinar on Monday, September 11, 2023 at 1:00 p.m. Eastern Time
(PR Newswire)
Aug-09-23 09:35AM
MIRA Pharmaceuticals, Inc. Discusses Potential of Revolutionary THC Analog Drug, MIRA1a, with The Stock Day Podcast
(ACCESSWIRE)
Aug-03-23 02:40PM
MIRA Pharmaceuticals debuts on the Nasdaq with plans to revolutionize medicinal CBD and THC
(News Direct)
MIRA Pharmaceuticals, Inc. operates as a clinical development stage biopharmaceutical company. The company engages in developing its product candidate, MIRA1a, as a synthetic cannabinoid analog for treating anxiety & chronic pain by targeting the cannabinoid type 1 and type 2 (CB1 and CB2) receptors. MIRA Pharmaceuticals was founded by Adam Kaplin on September 3, 2020 and is headquartered in Miami, FL.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Aminov ErezChief Executive OfficerMay 21 '24Buy0.948,7008,176382,200May 22 05:42 PM
McNulty Brian Patrick10% OwnerDec 11 '23Sale1.5546,00571,496660,000Dec 27 05:33 PM
McNulty Brian Patrick10% OwnerDec 08 '23Sale1.6119,05330,633683,002Dec 27 05:33 PM
McNulty Brian Patrick10% OwnerDec 07 '23Sale1.8933,33363,156692,529Dec 27 05:33 PM
McNulty Brian Patrick10% OwnerDec 06 '23Sale2.9527,73381,785709,196Dec 27 05:33 PM
McNulty Brian Patrick10% OwnerDec 04 '23Sale3.9861,331244,097723,062Dec 27 05:33 PM
McNulty Brian Patrick10% OwnerNov 30 '23Sale3.774,84218,273753,728Dec 27 05:33 PM
McNulty Brian Patrick10% OwnerNov 29 '23Sale3.987,39929,445756,149Dec 27 05:33 PM
McNulty Brian Patrick10% OwnerNov 28 '23Sale4.00241964759,849Dec 27 05:33 PM
McNulty Brian Patrick10% OwnerNov 27 '23Sale4.006,42525,715759,969Dec 27 05:33 PM
McNulty Brian Patrick10% OwnerNov 21 '23Sale5.005,00025,000763,181Dec 27 05:33 PM
McNulty Brian Patrick10% OwnerNov 20 '23Sale5.0726,733135,523765,681Dec 27 05:33 PM
Cappy George10% OwnerAug 07 '23Buy7.00119,048833,3362,859,318Aug 24 05:38 PM
Cappy George10% OwnerAug 02 '23Buy7.00157,1701,100,1902,740,270Aug 04 01:42 PM
open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR
affiliate • advertise • toggle light mode • contact • privacy • help
do not sell my data • privacy settings
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2024 FINVIZ.com. All Rights Reserved.